Literature DB >> 8911586

Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease.

S J Ferrando1, T L Wall, S L Batki, J L Sorensen.   

Abstract

This study describes the relationship between the need for psychiatric consultation, illicit drug use, and zidovudine (AZT) adherence in HIV-infected injection drug users (IDUs) in methadone maintenance treatment (MMT). The treatment records of 57 IDUs in MMT who had been prescribed AZT between May and August of 1991 were reviewed. Those who required psychiatric consultation (P+, N = 46, 81%) were compared with those who did not require psychiatric consultation (P-, N = 11, 19%) on adherence to AZT treatment (using the mean corpuscular volume [MCV] as a biological marker), on recent illicit drug use, and on CD4 lymphocyte (T cell) count changes from the beginning to the end of AZT treatment. The P+ subjects were less likely than P- subjects to adhere to AZT treatment: fewer in the P+ group had an MCV outside of the normal range, and P+ subjects had a lower average monthly increase in MCV since the beginning of AZT treatment. Recent illicit drug use and CD4 lymphocyte count changes from the beginning to the end of AZT treatment did not show group differences. Psychiatric morbidity among HIV-infected IDUs in MMT is common, and may contribute to poor adherence to AZT treatment. Psychiatric screening and adherence-enhancing interventions should be targeted to IDUs entering drug treatment programs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911586     DOI: 10.3109/00952999609001674

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  11 in total

1.  When should we delay highly active antiretroviral therapy?

Authors:  D R Bangsberg; A Moss
Journal:  J Gen Intern Med       Date:  1999-07       Impact factor: 5.128

2.  Sero-positive African Americans' beliefs about alcohol and their impact on anti-retroviral adherence.

Authors:  Andrea Sankar; Tracy Wunderlich; Stewart Neufeld; Mark Luborsky
Journal:  AIDS Behav       Date:  2007-03

3.  Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: the impact of social network factors, side effects, and perceived treatment efficacy.

Authors:  Penelope A Demas; Donald M Thea; Jeremy Weedon; Janis McWayne; Mahrukh Bamji; Genevieve Lambert; Ellie E Schoenbaum
Journal:  Women Health       Date:  2005

4.  Perspective: recognizing resistance.

Authors:  Diana Sylvestre
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

Review 5.  Prevention and treatment of hepatitis C in injection drug users.

Authors:  Brian R Edlin
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

6.  The relationship between injection and noninjection drug use and HIV disease progression.

Authors:  Han-Zhu Qian; Samuel E Stinnette; Peter F Rebeiro; Aaron M Kipp; Bryan E Shepherd; Charles P Samenow; Cathy A Jenkins; Paul No; Catherine C McGowan; Todd Hulgan; Timothy R Sterling
Journal:  J Subst Abuse Treat       Date:  2011-02-23

7.  Problem drinking and medication adherence among persons with HIV infection.

Authors:  R L Cook; S M Sereika; S C Hunt; W C Woodward; J A Erlen; J Conigliaro
Journal:  J Gen Intern Med       Date:  2001-02       Impact factor: 5.128

8.  Taking antiretroviral therapy for HIV infection: learning from patients' stories.

Authors:  M B Laws; I B Wilson; D M Bowser; S E Kerr
Journal:  J Gen Intern Med       Date:  2000-12       Impact factor: 5.128

Review 9.  Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review.

Authors:  Michael-John S Milloy; Brandon D L Marshall; Thomas Kerr; Jane Buxton; Tim Rhodes; Julio Montaner; Evan Wood
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

10.  Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users.

Authors:  Frederick L Altice; Sandra Springer; Marta Buitrago; David P Hunt; Gerald H Friedland
Journal:  J Urban Health       Date:  2003-09       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.